Allurion Technologies Holdings Inc. has announced the publication of a new peer-reviewed, case-controlled study evaluating the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone. The results, which have already been published, indicate that the combination of the Allurion Smart Capsule and individualized lifestyle intervention led to an average weight reduction of 20% and nearly twice as much fat reduction at 36 weeks, without adverse effects on muscle mass. The study, which included 1,143 patients with a BMI of 30 kg/m2 or higher, also reported that the safety profile of the Allurion Smart Capsule was better than bariatric surgery and GLP-1 therapy, with efficacy comparable to bariatric surgery and higher than high-dose GLP-1 therapy in real-world settings.